[{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Intra-Cellular Therapies \/ Johnson & Johnson"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hikma Pharmaceuticals \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/2C\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sunshine Biopharma \/ Inapplicable"}]